InMed Pharmaceuticals (INM) EBT Margin (2021 - 2025)
InMed Pharmaceuticals (INM) reported EBT Margin of 247.29% for Q4 2025, down 1566.0% on a YoY basis from 16.87% in Q4 2024, and down 60.4% quarter-over-quarter from 154.17% in Q3 2025.
InMed Pharmaceuticals (INM) EBT Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported EBT Margin for 5 years, with the latest figure at 247.29% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 1566.0% year-over-year to 247.29%; the trailing twelve-month figure through Dec 2025 stood at 158.18% (up 544.0% YoY), and the FY2025 full-year result was 165.14%, up 165.0% from the prior year.
- EBT Margin for Q4 2025 stood at 247.29%, down from 154.17% in the prior quarter.
- The five-year high for EBT Margin was 14.56% in Q2 2023, with the low at 1615.6% in Q4 2021.
- Historically, EBT Margin has averaged 455.36% across 5 years, with a median of 193.09% in 2023.
- Annual changes were most pronounced in 2023 — EBT Margin soared 151431 bps — and 2024, when it sank 13590 bps.
- InMed Pharmaceuticals' EBT Margin stood at 1615.6% in 2021, then jumped by 72 bps to 446.61% in 2022, then surged by 73 bps to 119.19% in 2023, then slumped by 94 bps to 231.63% in 2024, then dropped by 7 bps to 247.29% in 2025.
- The last three EBT Margin figures came in at 247.29% (Q4 2025), 154.17% (Q3 2025), and 100.13% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -156.77% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 41.45% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.70% |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -247.29% |
| Sep 30, 2025 | -154.17% |
| Jun 30, 2025 | -100.13% |
| Mar 31, 2025 | -163.85% |
| Dec 31, 2024 | -231.63% |
| Sep 30, 2024 | -132.68% |
| Jun 30, 2024 | -150.47% |
| Mar 31, 2024 | -146.93% |
| Dec 31, 2023 | -119.19% |
| Sep 30, 2023 | -281.29% |
| Jun 30, 2023 | -14.56% |
| Mar 31, 2023 | -193.09% |
| Dec 31, 2022 | -446.61% |
| Sep 30, 2022 | -1,092.12% |
| Jun 30, 2022 | -1,528.88% |
| Mar 31, 2022 | -1,122.69% |
| Dec 31, 2021 | -1,615.60% |